Bicara Therapeutics Inc. (BCAX) stock forecast and price target
Price $10.02 · data as of November 13, 2026
12-month price target
Average target$32.17
Upside / downside+221.0%
Analysts12
ConsensusStrong buy
Low $8.00Average $32.17High $43.00
Gold marker: average target · white marker: today’s price ($10.02)
Analyst ratings
Strong buy 3Buy 10Hold 0Sell 1Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-3.63 | −44.0% | $0 |
| Next fiscal year ends December 31, 2027 | $-3.89 | −7.3% | $0 |
| Next quarter ends December 31, 2026 | $-0.86 | −26.6% | $0 |
| Quarter after ends March 31, 2027 | $-1.01 | −9.1% | $0 |
Consensus of the analysts covering Bicara Therapeutics, updated daily. In the last 30 days 1 estimates were raised and 1 lowered.
Frequently asked questions
What is the Bicara Therapeutics stock price target?
The average 12-month target from 12 analysts is $32.17, 221.0% above the current price of $10.02 Targets range from $8.00 to $43.00.
Is Bicara Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (3 strong buy, 10 buy, 1 sell). Ratings are opinions, not guarantees; this is not investment advice.
How much is Bicara Therapeutics expected to earn?
Analysts expect EPS of $-3.63 for the fiscal year ending December 31, 2026 and $-3.89 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.